Moreover, the characterisation of the cancer-associated PTEN Y138L mutation by Davidson et al., with specific loss of PTEN protein phosphatase activity and retention of lipid phosphatase activity, presents a new tool that should be investigated in vivo25. The gene discussed is PTEN; the disease is cancer.